Skip to Content

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

In this MEDtalk, Maria Teresa Bourlon presents the updated efficacy in the intention-to-treat population at 55-month median follow-up on the CheckMate 9ER phase 3 trial. The results show that the combination therapy with nivo+cabo continues to maintain meaningful long-term benefits in efficacy endpoints, such as progression-free survival, overall survival, and overall response rates.

Maria Teresa Bourlon

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top